To summarize the open-label extension of VESPER-1, berobenatide 2.4 mg weekly demonstrated 16% weight loss at 32 weeks, a favorable benefit-risk profile for monthly dosing, and safety and tolerability consistent with the class with no discontinuations related to gastrointestinal adverse events, and the gastrointestinal tolerability was excellent, said John B
Notably, GLP-1MK-801 also resulted in lower plasma triglycerides compared with MK-801 monotherapy
GLP-1 medications are prescription-only in the United States
Other than direct consequences, such as degenerative arthritis and sleep apnea, its controversial whether being overweight in and of itself causes a health risk
You have them in your brain (hypothalamus, brainstem), pancreas (beta cells and alpha cells), stomach, intestines, heart, and kidneys
Or Consult: Contact your provider or care team and ask them to enter a consult for MOVE